|1.||Afra, Dénes: 2 articles (06/2008 - 01/2002)|
|2.||Simonetti, G: 1 article (07/2014)|
|3.||Botturi, A: 1 article (07/2014)|
|4.||Lamperti, E: 1 article (07/2014)|
|5.||Gaviani, P: 1 article (07/2014)|
|6.||Innocenti, A: 1 article (07/2014)|
|7.||Silvani, A: 1 article (07/2014)|
|8.||Olasz, Lajos: 1 article (06/2010)|
|9.||Orsi, Eniko: 1 article (06/2010)|
|10.||Nyárády, Zoltán: 1 article (06/2010)|
|1.||Breast Neoplasms (Breast Cancer)
12/01/1982 - "Dibromodulcitol in the treatment of breast cancer."
11/01/1976 - "Evaluation of an intermittent schedule of dibromodulcitol in breast cancer."
12/01/1984 - "Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer."
12/01/1984 - "Thirty-eight evaluable patients with metastatic breast cancer refractory to hormonal therapy and multiple chemotherapy regimens were treated with mitolactol at a dose of 130 mg/m2/day orally for 10 days every 6 weeks. "
10/01/1983 - "Evaluation of mitolactol in women with advanced breast cancer and prior chemotherapy exposure."
01/01/1981 - "Phase II study of dibromodulcitol in colorectal, kidney, and other carcinomas."
08/01/1987 - "Dibromodulcitol treatment induced histological damages in solid Ehrlich carcinoma which increased on the effect of parallelly applied local fractionated X-irradiation. "
04/01/1984 - "Antitumor activity has been documented in this pilot study utilizing mitolactol in patients with advanced carcinoma of the cervix. "
01/01/1976 - "The effect of dibromodulcitol (Elobromolr, Mitolactolr, nsc 104 800) on the postoperative recurrences of the Guerin carcinoma of the rat."
09/01/1984 - "[Dibromodulcitol in combination with actinotherapy of spinocellular carcinoma]."
|3.||Brain Neoplasms (Brain Tumor)
11/13/1994 - "[Pharmacokinetic study of dibromodulcitol in children with brain tumors]."
11/01/1990 - "Dibromodulcitol (DBD) is an anticancer agent that is cytotoxic against animal and human brain tumors in vivo. "
03/01/1997 - "To evaluate a combination of thioguanine, procarbazine, dibromodulcitol, CCNU (CCNU), fluorouracil, and hydroxyurea (TPDC-FuHu), designed to improve the efficacy of CCNU, in the treatment of recurrent metastatic brain tumors. "
|4.||Lewis Lung Carcinoma
|5.||Melanoma (Melanoma, Malignant)
06/01/1985 - "Phase II study of mitolactol in advanced malignant melanoma."
01/01/1985 - "This study shows that mitolactol has moderate activity against advanced melanoma, and the drug deserves further study in combination with nonmyelotoxic drugs."
01/01/1985 - "The Central Pennsylvania Oncology Group conducted a phase II study of mitolactol in advanced metastatic melanoma to determine the overall survival rate and duration of response to this agent. "
01/01/1985 - "Phase II study of mitolactol in metastatic malignant melanoma."
10/01/1984 - "Twenty-four patients were evaluated in a non-randomized study to assess the effectiveness of dibromodulcitol (DBD) in Stage IV melanoma. "
|9.||Leucovorin (Folinic Acid)
|1.||Drug Therapy (Chemotherapy)
|3.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)